Agios Pharmaceuticals, Inc. Earnings

Agios Pharmaceuticals, Inc.’s revenue jumped 6.56% since last year same period to $8.73Mn in the Q1 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated -18.68% fall in its revenue since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit fell -9.49% since last year same period to $-89.29Mn in the Q1 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 7.49% jump in its net profits since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit margin fell -2.75% since last year same period to -1023.25% in the Q1 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated -13.75% fall in its net profit margins since last 3-months.

Agios Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 3.05.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.92 - a -6.08% fall from last quarter’s estimates.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -1.92.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Agios Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.